title: Matrix metalloproteinase-2 deletions protect against hemorrhagic transformation after 1 h of cerebral ischemia and 23 h of reperfusion.
abstract: Although elevated matrix metalloproteinase (MMP)-2 levels were highly related to the degradation of tight junction (TJ) proteins and basal lamina and neuronal injury after ischemia, until very recently, little experimental evidence was available to test the role of the MMP-2 knockout (KO) in blood-brain-barrier (BBB) injury and the development of hemorrhage transformation (HT). Here, we assessed the role of the MMP-2 KO in BBB injury, HT and other brain injuries after 1h of ischemia and 23 h of reperfusion. Middle cerebral artery occlusion (MCAO) was performed in MMP-2 KO mice. Reperfusion was started 1h after the onset of MCAO. All mice were sacrificed 24h after the MCAO. MMP-2 deficiency reduced the decrease in protein levels of collagen IV and cellular membrane occludin (p<0.01 and 0.05 vs. wild-type (WT), respectively) and attenuated increase in cytosol occludin level in ischemic brain (p<0.01 vs. WT). The hemorrhage volume and brain infarction were significantly decreased in both the cortex and striatum in the MMP-2 KO mice (p<0.01 vs. WT). The MMP-2 KO also had reduced brain swelling in the cortex and improved neurological deficits (p<0.01 vs. WT). These studies provide direct evidence that targeting MMP-2 will effectively protect against collagen and occludin loss and HT after ischemia and reperfusion.
authors.affiliation: Department of Neurology, University of Cincinnati, Cincinnati, OH 45267-0532, USA. Electronic address: lua@ucmail.uc.edu.
authors.forename: A
authors.initials: A
authors.lastname: Lu
authors.forename: Y
authors.initials: Y
authors.lastname: Suofu
authors.forename: F
authors.initials: F
authors.lastname: Guan
authors.forename: J P
authors.initials: JP
authors.lastname: Broderick
authors.forename: K R
authors.initials: KR
authors.lastname: Wagner
authors.forename: J F
authors.initials: JF
authors.lastname: Clark
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001929:Brain Edema / Q000201:enzymology / Q000209:etiology; D020520:Brain Infarction / Q000201:enzymology / Q000209:etiology; D002545:Brain Ischemia / Q000150:complications* / Q000235:genetics; D002462:Cell Membrane / Q000378:metabolism / Q000473:pathology; D002543:Cerebral Hemorrhage / Q000201:enzymology / Q000209:etiology / Q000517:prevention & control; D003094:Collagen / Q000378:metabolism; D003600:Cytosol / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D005786:Gene Expression Regulation / Q000235:genetics*; D020778:Matrix Metalloproteinase 2 / Q000172:deficiency*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D062793:Occludin / Q000378:metabolism; D015427:Reperfusion Injury / Q000235:genetics / Q000503:physiopathology*
chemical_list: D062793:Occludin; D003094:Collagen; D020778:Matrix Metalloproteinase 2
keywords: 2,3,5-triphenyltetrazolium chloride; BBB; EDTA; FGF; FGF receptor type 1; FGFR1; HT; KO; MCAO; MCID; MMP; MMP-2 knockout; SDS; TJ; TTC; WT; blood–brain barrier; cerebral ischemia; ethylenediaminetetraacetic acid; fibroblast growth factor; hemorrhagic transformation; knockout; matrix metalloproteinase; mice; microcomputer image device; middle cerebral artery occlusion; rCBF; regional cerebral blood flow; sodium dodecyl sulfate; tight junction; wild-type
references.citation: Exp Neurol. 2009 Apr;216(2):407-12
references.pmid: 19162014
references.citation: Brain Res. 2005 Nov 30;1063(2):168-79
references.pmid: 16271356
references.citation: Neuroreport. 2001 Sep 17;12(13):3003-7
references.pmid: 11588620
references.citation: Brain Res. 2010 Apr 22;1326:114-27
references.pmid: 20197061
references.citation: J Cereb Blood Flow Metab. 2006 Jun;26(6):797-810
references.pmid: 16192992
references.citation: Stroke. 2003 Sep;34(9):2221-7
references.pmid: 12920264
references.citation: J Neurosci. 1996 Oct 1;16(19):6236-45
references.pmid: 8815904
references.citation: Cerebrovasc Dis. 2013;35(6):514-20
references.pmid: 23817219
references.citation: J Cereb Blood Flow Metab. 2007 Aug;27(8):1431-43
references.pmid: 17245419
references.citation: Protein Sci. 2006 Dec;15(12):2805-15
references.pmid: 17088321
references.citation: J Neurochem. 2002 Apr;81(2):355-64
references.pmid: 12064483
references.citation: J Cereb Blood Flow Metab. 2007 Apr;27(4):697-709
references.pmid: 16850029
references.citation: Exp Neurol. 2008 Apr;210(2):549-59
references.pmid: 18187134
references.citation: J Cereb Blood Flow Metab. 1999 Jun;19(6):624-33
references.pmid: 10366192
references.citation: Anesth Analg. 1997 Sep;85(3):593-9
references.pmid: 9296415
references.citation: J Biol Chem. 2006 Mar 31;281(13):8379-88
references.pmid: 16439355
references.citation: Am J Physiol Cell Physiol. 2000 Jul;279(1):C21-30
references.pmid: 10898713
references.citation: J Biol Chem. 1997 Sep 5;272(36):22389-92
references.pmid: 9278386
references.citation: Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7069-74
references.pmid: 8692946
references.citation: Neuroscience. 2012 Jun 14;212:180-9
references.pmid: 22521821
references.citation: Stroke. 1998 Oct;29(10):2189-95
references.pmid: 9756602
references.citation: Nat Neurosci. 2003 Oct;6(10):1064-71
references.pmid: 14502291
references.citation: Stroke. 2001 Jan;32(1):147-53
references.pmid: 11136930
references.citation: J Neurosci. 2012 Feb 29;32(9):3044-57
references.pmid: 22378877
references.citation: J Neurosci Methods. 2008 Aug 30;173(2):291-4
references.pmid: 18611410
references.citation: Cardiovasc Res. 2002 Nov;56(2):284-92
references.pmid: 12393099
references.citation: J Cereb Blood Flow Metab. 2012 May;32(5):919-32
references.pmid: 22354151
references.citation: J Biomed Biotechnol. 2011;2011:464701
references.pmid: 21331357